Actinium Pharmaceuticals, Inc. has entered a collaboration with IsoTherapeutics Group to complete studies required for a new manufacturing process for Actimab-A, Actinium’s Phase 1/2 trial for newly diagnosed acute myeloid leukemia (AML) patients in a single arm multicenter trial.   According to the companies, the newly developed manufacturing process results in a tenfold improvement of manufacturing yield. IsoTherapeutics will perform additional studies to generate the necessary documenta...